The multifaceted role of MUC1 in tumor therapy resistance

Weiqiu Jin; Mengwei Zhang; Changzi Dong; Lei Huang; Qingquan Luo

doi:10.1007/s10238-022-00978-y

The multifaceted role of MUC1 in tumor therapy resistance

Clin Exp Med. 2023 Sep;23(5):1441-1474. doi: 10.1007/s10238-022-00978-y. Epub 2022 Dec 23.

Authors

Weiqiu Jin^#^{1

2}, Mengwei Zhang^#^{2

3}, Changzi Dong⁴, Lei Huang^{5

6}, Qingquan Luo⁷

Affiliations

¹ Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200025, China.
² Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
³ Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
⁴ Department of Bioengineering, School of Engineering and Science, University of Pennsylvania, Philadelphia, 19104, USA.
⁵ Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. leihuang@shsmu.edu.cn.
⁶ Innovative Research Team of High-Level Local Universities in Shanghai, Shanghai, China. leihuang@shsmu.edu.cn.
⁷ Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200025, China. luoqingquan@hotmail.com.

^# Contributed equally.

PMID: 36564679
DOI: 10.1007/s10238-022-00978-y

Abstract

Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized.

Keywords: Biotherapy; Cancer therapy resistance; Chemotherapy; MUC1; Radiation therapy.

Publication types

Review

MeSH terms

Cell Line, Tumor
Humans
Mucin-1* / genetics

Substances

Mucin-1
MUC1 protein, human